Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 1.00 |
| ▸ | CCND1 | P24385 | 18/20 | 1.00 |
| ▸ | CCND2 | P30279 | 15/20 | 1.00 |
| ▸ | CCND3 | P30281 | 15/20 | 1.00 |
| ▸ | CDK2 | P24941 | 11/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 9/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 9/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 8/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 6/20 | 1.00 |
| ▸ | CDK1 | P06493 | 6/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 6/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 5/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 5/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 5/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 5/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 4/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 0.98 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.98 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264602 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL30418772 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5262935 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5264325 | 0.95 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5265688 | 0.94 | CDK4 (0.89) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5263022 | 0.92 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5266784 | 0.92 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5263902 | 0.92 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5268232 | 0.92 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5263278 | 0.92 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | claimed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | claimed |
| EP-2073803-B1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2018-09-19 | — | — | EP | disclosed |
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-8916552-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8541461-B2 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8435970-B2 | Title compound is drug AT-9283, inhibitor of Cyclin Dependent Kinases (CDK kinases), Aurora kinases and Glycogen Synthase Kinase-3 (GSK3) | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CDK4 1/4885CCND1 23/4885CCND2 25/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | CDK4 14/4885CCND1 210/4885CCND2 272/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | CDK4 991/4885CCND1 1966/4885CCND2 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.